TUESDAY, Oct. 9, 2018 — Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks, according to a phase 2 study published in the Oct. 4 issue of the New England Journal of Medicine. Kim Papp, M.D.,